<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03058185</url>
  </required_header>
  <id_info>
    <org_study_id>CPP58-12, ID-RCB2012-A00791</org_study_id>
    <nct_id>NCT03058185</nct_id>
  </id_info>
  <brief_title>Observatoire Des Patients Atteints de Laminopathies et Emerinopathies (Observatory for PAtients With Laminopathies and Emerinopathies)</brief_title>
  <acronym>OPALE</acronym>
  <official_title>Observatoire Des Patients Atteints de Laminopathies et Emerinopathies (Observatory for PAtients With Laminopathies and Emerinopathies)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pitié-Salpêtrière Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pitié-Salpêtrière Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laminopathies and emerinopathies are complex group of rare disorders due to mutations in
      A-type lamins (LMNA) and Emerin (EMD) genes. Among them, disorders affecting skeletal and/or
      cardiac muscles are the most frequent clinical manifestations, with cardiac disease being a
      major cause of death. Remarkable progress has been made in the description of the clinical
      and genetic spectrum of these diseases since the 1990's. Until now, precise
      phenotype/genotype relations remain elusive. As for several other neuromuscular disorders,
      apart from symptomatic treatments, there is currently no specific treatment to prevent or
      slow down the progression of the disease. The OPALE registry is a multicentre web-based
      registry dedicated to laminopathy and emerinopathy French patients. OPALE has been approved
      by ethical and regulatory authorities. Its main inclusion criteria is the presence of a
      proven pathogenic LMNA and/or EMD gene mutation.

      The OPALE objectives are to provide a tool allowing detailed capture of patient genetic,
      neurological, cardiological, endocrinological and respiratory assessments, in order to allow
      i) precise disease natural history, ii) evaluation of different disease complication
      frequency and iii) identification of prognosis factors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2013</start_date>
  <completion_date type="Anticipated">July 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 11, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Comprehensive clinical evaluation of individuals with geneticaly proven mutations in LMNA or EMD genes according to the study protocol, in order to evaluate disease progression</measure>
    <time_frame>yearly up to 10 years</time_frame>
    <description>Comprehensive clinical evaluation of individuals with geneticaly proven mutations in LMNA or EMD genes according to the study protocol, in order to evaluate disease progression</description>
  </primary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Laminopathies</condition>
  <condition>Emerinopathies</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a proven pathogenic LMNA and/or EMD gene mutation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of a proven pathogenic LMNA and/or EMD gene mutation

          -  Regular followup in France.

          -  Signed informed consent

        Exclusion Criteria:

        -Signed informed refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Cathy CHIKHAOUI</last_name>
    <phone>+33142165873</phone>
    <email>k.chikhaoui@institut-myologie.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Marseille</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du-Rhône</state>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AnnaChiara DE SANDRE-GIOVANNOLI, Md, PhD</last_name>
      <phone>+33 491 38 66 27</phone>
      <email>annachiara.desandre@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Bénédicte GABORIT</last_name>
      <phone>+33 491 96 87 23</phone>
      <email>benedicte.gaborit@ap-hm.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guilhem SOLE, MD</last_name>
      <phone>+33 557 82 13 80</phone>
      <email>guilhem.sole@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Frédéric SACHER, MD</last_name>
      <phone>+33 557 65 64 71</phone>
      <email>frederic.sacher@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre de référence maladies neuromusculaires ile de France, Hôpital Necker Enfants malades</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle DESGUERRE, MD, PhD</last_name>
      <phone>+33 144 49 58 36</phone>
      <email>isabelle.desguerre@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christine BARNERIAS, MD</last_name>
      <phone>+33 144 49 58 36</phone>
      <email>christine.barnerias@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <state>Normandie</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien Labonbarda, MD, PhD</last_name>
      <email>labombarda-f@chu-caen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Françoise Chapon, MD, PhD</last_name>
      <email>chapon-f@chu-caen.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Stéphane Schaeffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de référence des maladies neuromusculaires Ile de France, Hôpital Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <state>Yvelines</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana QUIJANO-ROY, MD, PhD</last_name>
      <phone>+33 147 10 78 90</phone>
      <email>susana.quijano-roy@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Ivana DABAJ, MD</last_name>
      <phone>+33 147 10 78 90</phone>
      <email>ivana.dabaj@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre de référence maladies neuromusculaires,CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Durigneux, MD</last_name>
      <email>JuDurigneux@chu-angers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marco Spinazzi, MD</last_name>
      <phone>+33 241357933</phone>
      <email>Marco.Spinazzi@chu-angers.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre de référence des maladies neuromusculaires, CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Marie Cuisset, MD</last_name>
      <email>Jean-Marie.CUISSET@CHRU-LILLE.FR</email>
    </contact>
    <investigator>
      <last_name>Florence Petit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Tiffreau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Celine Tard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Christine Vantyghem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de référence des maladies neuromusculaires, CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Françoise Bouhour, MD</last_name>
      <phone>+33 4 72 11 80 63</phone>
      <email>francoise.bouhour@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Véronique Manel, MD</last_name>
      <phone>+33 4 72 38 56 86</phone>
      <email>veronique.manel@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Service d'endocrinologie, diabétologie et endocrinologie de la reproduction, Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne VIGOUROUX, MD, PhD</last_name>
      <phone>+33 171 97 09 78</phone>
      <email>corinne.vigouroux@inserm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Camille VATIER, MD, PhD</last_name>
      <phone>33 140 01 13 21</phone>
      <email>camille.vatier@inserm.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre de référence maladies neuromusculaires ile de France, GH Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy CHIKHAOUI</last_name>
      <phone>+33142165873</phone>
      <email>k.chikhaoui@institut-myologie.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de cardiologie, Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Duboc, MD, PhD</last_name>
      <email>denis.duboc@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Karim Wahbi, MD, PhD</last_name>
      <email>karim.wahbi@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre de référence maladies neuromusculaires ile de France, Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud ISAPOF, MD</last_name>
      <phone>+33 171 73 85 51</phone>
      <email>arnaud.isapof@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Michele MAYER, MD</last_name>
      <phone>+33 171 73 82 79</phone>
      <email>michele.mayer@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://epidemiologie-france.aviesan.fr/epidemiologie-france/fiches/observatoire-des-patients-atteints-de-laminopathies-et-emerinopathies</url>
    <description>Portail épidémiologie France</description>
  </link>
  <link>
    <url>http://www.orpha.net/consor/cgi-bin/ResearchTrials_RegistriesMaterials.php?lng=FR&amp;data_id=115641&amp;Nom%20du%20registre%20ou%20mat%E9riel=Observatoire-des-patients-atteints-de-laminopathies-et-emerinopathies&amp;title=Observatoire-des-patients-atteints-de-laminopathies-et-emerinopathies&amp;search=ResearchTrials_RegistriesMaterials_Simple</url>
    <description>Orphanet</description>
  </link>
  <link>
    <url>http://www.afm-telethon.fr/observatoire-opale-6702</url>
    <description>AFM-Telethon</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 15, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2017</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pitié-Salpêtrière Hospital</investigator_affiliation>
    <investigator_full_name>Bruno Eymard</investigator_full_name>
    <investigator_title>Clinical Professor-Head of the neuromuscular reference center</investigator_title>
  </responsible_party>
  <keyword>Lamin A/C</keyword>
  <keyword>Emerin</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

